"The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced.
Adalimumab is the first and o"...
AZOPT (brinzolamide ophthalmic suspension) 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
DOSAGE AND ADMINISTRATION
The recommended dose is one drop of AZOPT (brinzolamide ophthalmic suspension) 1% in the affected eye(s) three times daily. AZOPT (brinzolamide ophthalmic suspension) 1% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is used, the drugs should be administered at least ten (10) minutes apart.
Dosage Forms And Strengths
Solution containing 10 mg/mL brinzolamide.
AZOPT (brinzolamide ophthalmic suspension) 1% is supplied in plastic DROP-TAINER† dispensers with a controlled dispensing-tip as follows:
10 mL NDC 0065-0275-10
15 mL NDC 0065-0275-15
Storage And Handling
Store AZOPT (brinzolamide ophthalmic suspension) 1% at 4-30°C (39-86°F). Shake well before use.
Distributed By: ALCON LABORATORIES, INC., Fort Worth, Texas 76134 USA. Revised: July 2015This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/23/2015
Additional Azopt Information
Azopt - User Reviews
Azopt User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.